Consumer Genomics: Finding the There, There
This article was originally published in Start Up
A number of genomics firms, attempting to capitalize on both the consumer movement and the power of genetics to create a personalized approach to health care, are trying to create consumer businesses. The two nearest-term opportunities are in aggregating pre-stratified, genotyped patients for clinical trials, often by teaming up with consumer health web sites; and providing pharmacogenetic tests of certain well-known drug metabolism variants. But the players face major hurdles not merely in coming up with proprietary tests, but in getting around ethical, privacy, and reimbursement issues specifically related to genetics, as well as in the potential problem of alienating physicians. At the same time, paradoxically, the consumer may offer the best route to preparing a market for genomic testing, which is likely to be resisted by much of the medical establishment.
You may also be interested in...
New technologies enable the rapid processing of genetic information, but since gene data isn't associated with specific diseases and diseased tissues, in and of itself it isn't clinically useful. A new breed of start-ups aims to provide both the phenotypic and genotypic sides of the equation by creating databases of patients and patient samples. Still unclear is how much drug firms will pay for disease-associated gene data; genetics firms are taking various approaches to monetizing their databases, from focusing initially on high-value diagnostics to creating true target-discovery businesses, to selling their data along with associated software and services. There are also ethical issues to hammer out. The new companies must take care to protect patients' rights. They must consider the need for explicit consent to use the information collected from patients, especially when they are participating in research whose purpose is as yet undefined.
It is a world, at least the US corner of it, in which any common understanding of drug value is confused by opposing incentives – to opacity and transparency, to looking at benefit broadly or narrowly, long-term or short-term: value, in short, to whom?
Merck and UnitedHealth's Optum group have partnered to explore various value constructs.